Cancer clinical trials in the region Auvergne-Rhône-Alpes

447 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 2 Lung cancer #NCT04614103

LN-145 autologue chez les patients atteints d'un cancer du poumon non à petites cellules métastatique

NSCLC (Non-Small Cell Lung Cancer) Metastatic 1 2 Immunotherapy Chemotherapy Targeted therapy

ALK EGFR ROS-1

6 recruiting sites

Iovance Biotherapeutics

Phase 2 Colon cancer Rectal cancer #NCT05310643 #2024-516313-20-00

[NIPIRESCUE] Étude du NIVOLUMAB et de l'IPILIMUMAB chez les patients atteints d'un cancer colorectal métastatique dMMR et/ou MSI résistant à la monothérapie anti-PD1

Adenocarcinoma Metastatic MSI/dMMR 1 2 3 or more Immunotherapy Chemotherapy Targeted therapy

MSS/pMMR

9 recruiting sites

GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie

Phase 2 Colon cancer Rectal cancer #NCT04262687

[POCHI] Étude de la chimiothérapie et de l'immunothérapie comme traitement du cancer colorectal métastatique MSS avec infiltrat immunitaire élevé

Metastatic MSS/pMMR None 1 Systemic Treatment-Naive Surgery Chemotherapy

MSI/dMMR Immunotherapy Immunotherapy

58 recruiting sites

Fédération Francophone de Cancérologie Digestive

Phase 2 Breast cancer #NCT05386108 #2024-512878-98-00

[ELECTRA] Étude sur l'ABEMACICLIB et l'ELACESTRANT chez des patientes présentant des métastases cérébrales dues à un cancer du sein RH+/HER2-

HER2 Negative HR Positive Metastatic 1 2 3 or more Chemotherapy Targeted therapy Hormone therapy

Systemic Treatment-Naive

9 recruiting sites

Stemline Therapeutics, Inc.

Phase 2 Lung cancer #NCT06656598 #2024-517316-29-00

[SPORADIC] Chimiothérapie adjuvante +/- CEMIPLIMAB et radiothérapie hypofractionnée séquentielle chez les patients inaptes ou âgés atteints d'un cancer du poumon de stade III

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced None Systemic Treatment-Naive

ALK EGFR ROS-1 Immunotherapy Chemotherapy

26 recruiting sites

Intergroupe Francophone de Cancérologie Thoracique

Phase 2 Lymphoma #NCT06526793

[SOUNDTRACK-B] AZD0486 en monothérapie chez les participants atteints de lymphome non hodgkinien récidivant/réfractaire à cellules B

B cell lymphoma Large B cell lymphoma Follicular lymphoma None Treated / Controled > 60 ml/min 50-60 ml/min 30-50 ml/min 2 3 or more

Systemic Treatment-Naive

5 recruiting sites

AstraZeneca

Phase 2 Lung cancer #NCT06465329 #2023-509806-31-00

Étude de l'association CEMIPLIMAB plus chimiothérapie versus CEMIPLIMAB plus chimiothérapie plus autres traitements contre le cancer chez les patients adultes atteints d'un cancer du poumon non à petites cellules opérable

NSCLC (Non-Small Cell Lung Cancer) Localized None Systemic Treatment-Naive

ALK EGFR Radiotherapy

7 recruiting sites

Regeneron Pharmaceuticals

Phase 2 Lymphoma #NCT04728893 #2023-504931-42-00

[MK-1026-003] Efficacité et innocuité du NEMTABRUTINIB (MK-1026) chez les participants atteints d'hémopathies malignes Cohortes E à G

B cell lymphoma Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma None Treated / Controled 1 2 3 or more Chemotherapy Targeted therapy Monoclonal antibodies

Systemic Treatment-Naive

4 recruiting sites

Merck Sharp & Dohme LLC

Phase 2 Lung cancer #NCT03175224 #2024-514542-37-00

[SPARTA] APL-101 chez des patients atteints d'un CBNPC avec mutations c-MET entrainant le saut de l'EXON 14 - Cohorte C2

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR MET None 1 Targeted therapy

ALK BRAF KRAS G12C KRAS non G12C NTRK-1/2/3 RET ROS-1

5 recruiting sites

Apollomics

Phase 2 Lung cancer #NCT05609578 #2023-503714-77-00

Essai de phase 2 sur les thérapies combinées avec l'ADAGRASIB chez des patients atteints d'un cancer du poumon non à petites cellules avancé avec mutation KRAS G12C - Cohorte E

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Systemic Treatment-Naive

Targeted therapy Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies

8 recruiting sites

Mirati Thérapeutique Inc.